Navigation Links
Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
Date:5/19/2008

f any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. The half-life of the triphosphate in primary human hepatocytes is approximately 38 hours, which suggests the possibility for once-daily dosing. Early animal studies indicate that PSI-7851 can achieve concentrations of active triphosphate in the liver of up to 1,000 times higher than PSI-6130 at equivalent doses.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking sta
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
11. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... N.J. and FARMINGTON, Conn. ... Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company ... of diseases with significant unmet medical need and ... on a private placement of 2,050,000 shares of ... purchase 24,949,325 shares of its common stock.  Funds ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... 2007 - Enzon,Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today ... at the 2007,Annual Meeting of the American Association ... 14 - 18, 2007 in Los Angeles, CA., ... -- Abstract #1494: EZN-2208, a novel polyethyleneglycol-SN38,conjugate, has ...
... 13, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. today,announced that ... Meeting,of the American Association for Cancer Research (AACR) ... , Data being presented in a poster session ... selective and potent,inhibitor of cyclin-dependent kinases (CDKs) 2, ...
Cached Medicine Technology:Enzon to Present Preclinical Data From PEG-SN38 and PEGylation,Technology Studies at AACR Meeting 2Sunesis Pharmaceuticals to Present Data at the Annual Meeting of,the American Association for Cancer Research 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... , Effort aims to ... and professionals and pursue a co-operative and collaborative approach to ... , WASHINGTON, Aug. 4 The National ... a formal Memorandum of Understanding with two like-minded organizations--the Canadian ...
... , INDIANAPOLIS, Aug. 4 Arcadia Resources, Inc. ... innovative consumer health care services under the Arcadia HealthCare(SM) brand, ... provider Comfort Keepers((R) )to provide DailyMed(TM) for Comfort Keepers franchisees ... the program with Comfort Keepers will launch this month and ...
... , , , GLENWOOD, ... a recognized leader in personal and environmental radiation monitoring services, today reported financial ... , , Fiscal 2009 Third Quarter Highlights , ... to $23.5 million on continued global demand for InLight products and increased domestic ...
... , , CARLSBAD, Calif., Aug. ... leader in antisense therapeutics, today announced that management will present a ... on Tuesday, August 11, 2009, at 1:00 p.m. ET at the ... webcast of the presentation will be available on the "Investors & ...
... , , , ... GOHE) is pleased to advise the nutrition and investing community that ... Releases and corporate activities, are easily accessible by simply Googling Cholesterade(R). ... searching for recent updates on Go Healthy and/or its products, we ...
... , , HUNTINGTON ... sports water , is targeting the Southern California ... events throughout the late summer and fall. , ... the most demanding environments, from professional sporting events to serious amateur ...
Cached Medicine News:Health News:The National Health Care Anti-Fraud Association Signs Memorandum of Understanding With Canadian and European Anti-Fraud Organizations 2Health News:The National Health Care Anti-Fraud Association Signs Memorandum of Understanding With Canadian and European Anti-Fraud Organizations 3Health News:Arcadia HealthCare's DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care 2Health News:Arcadia HealthCare's DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care 3Health News:Arcadia HealthCare's DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care 4Health News:Arcadia HealthCare's DailyMed(TM) Signs Deal with Comfort Keepers(R), A Leading Provider of In-Home Care 5Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 2Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 3Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 4Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 5Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 6Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 7Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 8Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 9Health News:Go Healthy's Marquis Product Cholesterade(R) at Your Fingertips on Google 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: